

- **Name:** **Toshimi Takano**
 - **Current Position & Affiliation:** **Director,
Breast Medical Oncology Department,
The Cancer Institute Hospital of JFCR**
 - **Country:** **Japan**
-

• **Educational Background:**

- 2002-2005 Resident in Medical Oncology,
National Cancer Center Hospital, Tokyo, Japan
- 1998-2000 Resident in Internal Medicine and Clinical Oncology,
University of Tokyo Hospital, Tokyo, Japan
- 1994-1998 MD, University of Tokyo School of Medicine, Tokyo, Japan

• **Professional Experience:**

- 2020-Present Director, Breast Medical Oncology Department,
The Cancer Institute Hospital of JFCR, Tokyo, Japan
- 2016-Present Visiting Professor, Department of Breast Care,
Saitama Medical Center, Saitama Medical University, Saitama,
Japan
- 2010-2020 Head, Department of Medical Oncology,
Toranomon Hospital, Tokyo, Japan
- 2008-2010 Assistant Professor, Department of Medical Oncology,
Teikyo University School of Medicine, Tokyo, Japan
- 2005-2008 Chief Physician, Division of Medical Oncology,
Tokyo Kyosai Hospital, Tokyo, Japan

• **Professional Organizations:**

- 2014-Present Chairman of the Breast Cancer Committee,
West Japan Oncology Group, Osaka, Japan

• **Main Scientific Publications:**

- 1 Takano T: The era of meta-analyses-based recommendations: How were the Japanese Breast Cancer Society Clinical Practice Guidelines for Systemic Treatment of Breast Cancer established? Breast Cancer 27:332-333, 2020
- 2 Matsumoto K, Takahashi M, Sato K, et al: A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with

dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. *Cancer Med.* Published online Mar 13, 2020.

3 Yamashiro H, Iwata H, Masuda N, et al: Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. *Breast Cancer* Published online Feb 14, 2020

4 Tsuda H, Tsugawa K, Akiyama F, et al: Histological classification of breast tumors in the General Rules for Clinical and Pathological Recording of Breast Cancer (18th edition). *Breast Cancer* 27:309-321, 2020

5 Shimoi T, Nagai SE, Yoshinami T, et al: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. *Breast Cancer* 27:322-331, 2020

6 Miyashita M, Hattori M, Takano T, et al: Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials. *Breast Cancer* 27:347-354, 2020

7 Tanabe Y, Shiraishi S, Hashimoto K, et al: Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. *BMC Cancer* 20:325, 2020

8 Ishiguro H, Masuda N, Sato N, et al: A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. *Breast Cancer Res Treat* 180:715–724, 2020

9 Tamura K, Imamura CK, Takano T, et al: CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer (TARGET-1): a randomized, open-label, phase II study. *J Clin Oncol* 38:558-566, 2020

10 Ueno T, Masuda N, Sato N, et al: Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. *Jpn J Clin Oncol* 50:3–11, 2020

11 Takahashi M, Ozaki Y, Kizawa R, et al: Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. *BMC Cancer* 19:980, 2019

12 Ozaki Y, Masuda J, and Takano T: Sacituzumab govitecan-hziy in triple-negative breast cancer. (Correspondence) *N Engl J Med* 380:2382, 2019

13 Hamauchi S, Furuse J, Takano T, et al: A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. *Cancer* 125:4294-4302, 2019